0.10Open0.11Pre Close456 Volume2.31K Open Interest8.00Strike Price4.95KTurnover104.35%IV28.16%PremiumNov 15, 2024Expiry Date0.00Intrinsic Value100Multiplier15DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type0.1572Delta0.1808Gamma63.20Leverage Ratio-0.0108Theta0.0004Rho9.94Eff Leverage0.0031Vega
Recursion Pharmaceuticals Stock Discussion
🟢 Recently Announced:
⇒ $Organon & Co (OGN.US)$ to acquire Dermavant
⇒ $Rafael Holdings (RFL.US)$ to acquire Cyclo Tx
⇒Crown Lab to acquire $Revance Therapeutics (RVNC.US)$
⇒ $Recursion Pharmaceuticals (RXRX.US)$ merger with Exscientia
🔴 Recently Closed:
⇒ $Johnson & Johnson (JNJ.US)$ acquired V-Wave
⇒ Pharmacosmos acquired $GTHX
What companies will be next? 🤔
soon all bioinformatics stocks will be in double digit
Google Deepmind founder shares Nobel prize in chemistry for AI that unlocks the shape of proteins
Ghisallo Capital Management LLC Makes New Investment in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma
• First program to combine Recursion's end-to-end suite of AI-enabled active learning modules, resulting in target identification to IND enabling studies in under 18 months
• Plan to initiate dosing of Phase 1/2 in Q4 2024 to evaluate REC-1245 in a biomarker enriched patient po...
Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-in-Class Rbm39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma
She makes millionaires out of her clients, they all started as multimillionaires.
No comment yet